ABBV · News · 20260903N

Oncology Pipeline Progress

AbbVie Inc. · 2026-09-03 · Importance 58 · Surprise 82

AbbVie reported positive topline Phase 3 CERVINO results for etentamig, an investigational BCMA×CD3 bispecific T-cell engager in triple-class-exposed relapsed or refractory multiple myeloma. Etentamig produced a 74% objective response rate and reduced the risk of disease progression or death by 60%, with a progression-free-survival hazard ratio of 0.40 versus standard available therapies. Monthly dosing after a single step-up dose was associated with low rates of cytokine release syndrome and fatal infections. AbbVie plans to discuss the results with global regulatory authorities, but the product remains investigational and has not been approved.

Key facts

• Etentamig achieved a 74% objective response rate (ORR) in the Phase 3 CERVINO trial versus investigator's choice of standard available therapies in triple-class exposed relapsed/refractory multiple myeloma. source
• Etentamig reduced the risk of disease progression or death by 60% versus standard available therapies in the Phase 3 CERVINO trial (progression-free survival, hazard ratio 0.40). source
• AbbVie said the CERVINO results support the potential of etentamig to enable treatment across a range of settings, including outpatient and community-based care. source